Mean changes in the modified total Sharp score from baseline to month @ were significantly smaller in the tofacitinib groups than in the methotrexate group , but changes were modest in all three groups ( @ points in the @-mg tofacitinib group and < @ point in the @-mg tofacitinib group , as compared with @ points in the methotrexate group -LSB- P < @ for both comparisons -RSB- ) .